Nurix Therapeutics (NRIX) announced that the U.S. Food and Drug Administration has granted Fast Track designation for NX-5948, a highly selective degrader of Bruton’s tyrosine kinase, BTK, for the treatment of adult patients with relapsed or refractory Waldenstrom’s macroglobulinemia after at least two lines of therapy, including a BTK inhibitor.
Maximize Your Portfolio with Data Driven Insights:
- Leverage the power of TipRanks' Smart Score, a data-driven tool to help you uncover top performing stocks and make informed investment decisions.
- Monitor your stock picks and compare them to top Wall Street Analysts' recommendations with Your Smart Portfolio
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NRIX:
- Nurix Therapeutics price target raised to $35 from $30 at H.C. Wainwright
- Nurix Therapeutics initiated with a Buy at BTIG
- Nurix Therapeutics Reports Promising Trial Results for NX-5948
- Nurix Therapeutics holds a pharmaceutical update conference call
- Nurix Therapeutics initiated with an Outperform at BMO Capital